HOUSTON and SINGAPORE, Sept. 21, 2026 (GLOBE NEWSWIRE) --

休斯顿和新加坡，2026年9月21日（环球新闻社）--

Respiree

Respiree

, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced that ARKRAY & PARTNERS Pte. Ltd. (AAP) and Bizedge Capital have joined its Series A syndicate.

一家致力于开发人工智能（AI）平台以管理贯穿整个医疗健康 continuum 的疾病进展的健康科技公司今日宣布，ARKRAY & PARTNERS Pte. Ltd.（AAP）和 Bizedge Capital 已加入其 A 轮融资银团。

Respiree’s Series A round is led by We Venture Capital and ClavystBio, with previously announced participation from Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital and One Six 8 Ventures. The company plans to use the expanded round to continue growth of its global commercial team, as well as its US presence that has been growing from Houston at the Texas Medical Center (TMC) Innovation..

Respiree 的 A 轮融资由 We Venture Capital 和 ClavystBio 领投，此前已宣布 Adaptive Capital Partners、Greenwillow Capital Management、Seeds Capital 和 One Six 8 Ventures 参与投资。该公司计划利用本轮扩大的融资，继续壮大其全球商业团队，并加强在美国的业务布局，其在休斯顿德州医学中心（TMC）创新基地的业务正在不断增长。

“We continue to be encouraged by the interest we have received from leading investors around the world who bring strategic perspective and experience in solving health inefficiencies in specific markets,” said Dr. Gurpreet Singh, Founder and CEO of Respiree. “With the addition of AAP and Bizedge Capital, we are enhancing our ability to grow and invest globally.”.

Respiree 创始人兼首席执行官古尔普里特·辛格博士表示：“我们持续受到来自全球领先投资者的关注鼓舞，这些投资者带来了战略视角以及在特定市场解决健康领域低效问题的经验。”“随着 AAP 和 Bizedge Capital 的加入，我们将进一步增强在全球范围内增长和投资的能力。”

About Respiree

关于 Respiree

Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare’s care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression.

Respiree™ 是一家专注于人工智能与机器学习（AI/ML）的健康科技公司，致力于开发最先进的、经临床验证的人工智能（AI）技术，用于在医疗健康服务的全 continuum 中管理疾病进展。Respiree™ 的 1Bio™ 平台利用电子健康记录（EHR）数据及其专有的、获美国专利且经 FDA clearance 的传感器，对疾病进展进行纵向测量与追踪。

Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). (.

Respiree™ 现已在美国、澳大利亚及亚太地区（APAC）上市。Respiree™ 已获得 CE 认证，取得澳大利亚治疗商品管理局（TGA）的监管批准，并获得美国食品药品监督管理局（FDA）的 510(k) 许可。

www.respiree.com

www.respiree.com

)

）

About AAP

关于 AAP

AAP is an affiliate of ARKRAY, Inc. (headquartered in Kyoto, Japan), established in Sep 2012. It is the entity that operates 'ARKRAY 4U (ARKRAY FOR YOU),' a corporate venture capital (CVC) business dedicated to startups. With an investment allocation of JPY 10 billion, AAP primarily targets medical and healthcare-related startups and businesses in Japan and across Asia (including India and Israel), providing full support for the growth of innovative businesses and technologies.

AAP 是 ARKRAY 公司（总部位于日本京都）的关联公司，成立于2012年9月。该公司负责运营“ARKRAY 4U（ARKRAY FOR YOU）”，这是一项专注于初创企业的企业风险投资（CVC）业务。AAP 的投资规模为100亿日元，主要面向日本及亚洲地区（包括印度和以色列）的医疗与健康相关初创企业和业务，为创新业务和技术的成长提供全方位支持。

.

。

ARKRAY: (

爱科来：（

https://www.arkray.co.jp

https://www.arkray.co.jp

)| ARKRAY 4U: (

)| ARKRAY 4U: (

https://arkray4u.com/jp/cvc/

https://arkray4u.com/jp/cvc/

)

)

About Bizedge Capital

关于 Bizedge Capital

Bizedge Capital is a private investment firm focused on transformative companies in semiconductors, artificial intelligence, robotics, automation, and related fields. The firm does not chase logos or consensus rounds; its edge is proprietary intelligence that surfaces category-defining companies before the broader market catches on.

Bizedge Capital 是一家私人投资公司，专注于半导体、人工智能、机器人、自动化及相关领域的变革性企业。该公司不追逐知名项目或跟风投资共识轮次；其优势在于专有情报，能够在更广泛的市场察觉之前，发掘出定义行业品类的卓越企业。

Bizedge Capital is led by an 18-year VC veteran with a proven record of outcomes..

Bizedge Capital 由一位拥有18年风险投资经验、业绩卓著的资深人士领导。

Press Contact

媒体联系人

Cammy Duong

卡米·杜昂

LifeSci Communications

生命科学传播

cduong@lifescicomms.com

cduong@lifescicomms.com